Every letter we have printed

Fasting glucose and glycated haemoglobin can move in opposite directions over a short period and both be correct, because they describe different windows. Your table makes that visible in a way I have not seen elsewhere and I have borrowed it for teaching.

Baseline before rather than after is the single most valuable thing anybody can do, and it is the one thing that cannot be recovered later. A series without a starting point is much harder to read.

You describe the low-T3 pattern during energy restriction as benign adaptation. There is a body of opinion holding that it represents a genuine hypometabolic state requiring treatment. I do not hold that view but your readers will encounter it.

Buyers could create accountability tomorrow by asking for it. A purchase order that makes the certificate a term of the contract changes the position entirely, and it takes one sentence. The absence is a habit rather than a barrier.

Publishing the report number is a small accountability mechanism that already works. A number that can be quoted back to the issuing laboratory turns an image into something checkable, and the laboratories I have written to have all confirmed or denied within a week.

I supply research peptides and I want to push back on the specification column point. We sell from a catalogue of six hundred products. Writing a meaningful individual specification for each would take a year of somebody’s time, and a generic one would be exactly the decorative limit your article criticises. What would you actually have us do?

The word conforms is doing exactly the work you describe. A result of 97.8 against a specification of not less than 95 conforms; so does 99.6. The certificate that prints only the verdict has told me the material passed a test whose difficulty I am not allowed to know.

A baseline drawn before anything changes is worth more than any single later result, because it converts every subsequent value into a delta. The people who most regret not having one are the people looking at a first abnormal result with nothing to compare it against.

The discipline your article recommends is the right one: decide what you would do differently for each result before ordering it. Anything that fails that test is generating a number that will be worried about and not acted on.

My HbA1c was 6.1 before starting and 6.0 after four months. My clinic recorded this as no improvement in glycaemic control. My continuous monitor says my average glucose fell by a fifth over the same period. Which is measuring what?

What is missing from the mechanistic literature is anything about the microbiome, which is either an enormous omission or a sensible refusal to speculate. I have not been able to decide which, and neither, apparently, has anybody else.

Gastric emptying studies use several different methods and the numbers are not interchangeable. A scintigraphic half-time and a breath-test result answer related questions with different sensitivities, and papers are compared across methods routinely.

Your incidence tables are from the licensed products. I use compounded material at a concentration that does not match any pen. Are the figures transferable at all?

A protocol that permits both dose reduction and delay produces a tolerability figure describing a population that used those options. The figure is real and it is not a statement about the nominal schedule.

The costs compound quietly. A monthly figure that seemed acceptable at the start becomes a substantial annual commitment, and almost nobody in the accounts I read did that arithmetic before beginning.

What is not studied at all is what happens when somebody maintains for years and then has to stop for reasons outside their control. Every account of stopping in the literature is a planned stop, and planned stops are the minority case here.

Reasons cluster by phase. Early discontinuation is dominated by tolerability, late discontinuation by cost and circumstance, and reporting them as a single distribution loses the only structure in the data.

There is a category I would call loss of a reason to continue: the original motivation resolved, changed or receded. It is neither efficacy nor tolerability nor cost, and it may be the most common cause of a long arrangement ending quietly.

An honest presentation would give the ratio with its confidence interval and the sample size in the same sentence. Three numbers instead of one, and the impression created would be entirely different.

A great deal of the advice circulating in this area comes from athletic populations in energy balance, and the transfer to a substantial deficit in a very different population is rarely acknowledged. Naming the source population every time is the simplest corrective available.

Density and quality are different properties and only the first is measured. A change in density with unchanged architecture and a change in both have very different implications, and the common instrument cannot distinguish them.

Trifluoroacetate in the mobile phase is the practical villain. It pairs with basic residues, suppresses signal badly in the negative mode and moderately in the positive, and it is present because the chromatographer needed peak shape. The two halves of the experiment are working against each other and nobody owns the conflict.

Your account of electrospray is clear but it understates how much the additive matters. A mobile phase carrying trifluoroacetic acid suppresses ionisation substantially, which is why a laboratory running an excellent chromatographic method sometimes has to change it entirely before the same sample will give a usable spectrum. The two techniques want different solvents.

One request for the standing checklist. Ask whether the spectrum was acquired on the same sample preparation as the chromatography or on a separate weighing. If separate, the two sections of the certificate describe two different aliquots, and a reader is entitled to know that before drawing the two together.

The identity section I would accept contains four things: theoretical mass, observed mass, which mass convention was used, and the instrument. Three of the four cost nothing to print. Every certificate I hold from the wider market carries one of them.

Refrigerator temperature is assumed and rarely verified. Domestic units cycle over a wider band than people expect, and door shelves in particular spend a good deal of time well above the nominal figure.

Agitation matters. A vial carried in a bag for a day has experienced mechanical stress that a vial on a shelf has not, and interfacial stress is a recognised cause of aggregation in protein preparations generally.

Trace metals catalyse oxidation at concentrations far below anything a specification would flag. It is a plausible explanation for lot-to-lot variation that has nothing to do with the synthesis and everything to do with the water.

Deamidation is the pathway with the best-characterised kinetics and the least presence in popular discussion, presumably because the product has the same mass. It is invisible to the identity check most people rely on.

Light exposure gets one clause in your article and deserves more. Several of these sequences carry residues that photodegrade, and a clear vial on a bench under fluorescent light for a fortnight is a real exposure. Amber glass and a drawer are free.

Concentration matters for solution stability and it is chosen by the person reconstituting rather than by anybody who has studied it. A dilute preparation and a concentrated one are two different experiments, and both are described by the same anecdote.

Designing the error out is more effective than warning about it, which is the settled conclusion of every human-factors literature. In this market nobody controls the design, so the only available lever is the weakest one.

Air bubbles are a real volume error at these scales, because a bubble that would be trivial in a millilitre is substantial in a few hundredths. The remedy is unglamorous and the article should say it: draw slowly, hold the barrel upright, expel and re-draw.

The published work on this comes from long-established clinical practice in other therapeutic areas and transfers reasonably well. Citing the source would raise the standard of the discussion considerably.

One correction worth making loudly: the nominal mass on the label is not necessarily the mass in the vial. Where peptide content has not been determined, every concentration calculated from the label carries that uncertainty, and no amount of careful arithmetic removes it.

Between-subject variability in exposure is large and rarely mentioned in summaries aimed at general readers. Two people on an identical dose can sit some way apart in plasma concentration, which is a better explanation of divergent experience than most of the ones in circulation.

Time to steady state is determined by the elimination half-life and nothing else, and it differs between the compounds under discussion by enough to matter for how any schedule behaves in its first weeks.

I have read three separate articles this month describing cagrilintide as a GLP-1 agonist and one describing tirzepatide as "semaglutide with an extra bit". Thank you for the glossary. Please run it again.

Turnaround is the practical obstacle. A compendial sterility test takes a fortnight, which for material with a short commercial life is a genuine cost rather than an excuse. Rapid methods exist and validating one is not trivial.

Research-use framing lets the whole question be avoided legitimately. Material sold for laboratory use has no requirement of this kind attached to it, and the framing is accurate as well as convenient.